Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Breast cancer survivors' risk of interval cancers and false positive results in organized mammography screening

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Impact of chronic diseases on effect of breast cancer screening

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mortality and admission to intensive care units after febrile neutropenia in patients with cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Human papillomavirus types in cervical high-grade lesions or cancer among Nordic women-Potential for prevention

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Early indicators of primary brain tumours: a population-based study with 10 years’ follow-up

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Optimal Systemic Treatment of Advanced Bladder Cancer-A Moving Target

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gynaecological cancer leads to long-term sick leave and permanently reduced working ability years after diagnosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. The Use of Wearables in Clinical Trials During Cancer Treatment: Systematic Review

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

BACKGROUND: Bladder cancer (BC) patients with advanced disease have poor outcomes. The use of patient-reported outcomes (PROs) could lead to improvements in symptom management and hence quality of life (QoL). The aim of this study is to report correlations between selected PROs and QoL and thus to present symptoms that influence QoL. Identification of these symptoms during treatment can lead to earlier symptom management and thus secure improvements in QoL.

METHODS: BC patients in chemo- or immunotherapy for locally advanced or metastatic disease reported weekly PROs for the duration of their treatment. The PROs included EORTC QLQ-C30 and QLQ-BLM30 and 45 selected PRO-CTCAE items. Spearman's correlation analysis was performed for all PRO-CTCAE items and QLQ-C30 global QoL and subdomains.

RESULTS: In this study, 78 BC patients reported 724 questionnaires. Spearman's analysis showed significant correlations between almost all PRO-CTCAE items and the expected domain of QoL. The PRO-CTCAE items with the strongest correlations with QoL were anxiety (F, frequency item) and emotional function (rs = -0.603, P < .0001), concentration (S, severity item) and cognitive function (rs = -0.704, P < .0001), discouraged (F) and emotional function (rs = -0.659, P < .0001), fatigue (S) and role function (rs = -0.659, P < .0001) and sad (F) and emotional function (rs = -0.711, P < .0001). The weakest correlations were found for the PRO-CTCAE items urinary frequency, incontinence and urge, all with variations in the direction and significance of the correlations.

CONCLUSIONS: This study delivers information on which PROs may influence QoL for patients in clinical trials or daily clinic. Psychological issues have a strong impact on QoL and should be dealt with during treatment to secure the best possible QoL for BC patients.

Original languageEnglish
JournalCancer Medicine
Volume9
Issue number9
Pages (from-to)3078-3087
Number of pages10
ISSN2045-7634
DOIs
Publication statusPublished - May 2020

ID: 60921488